

Experiment Number: 99031 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract
CAS Number: 90045-36-6

Date Report Requested: 02/27/2012
Time Report Requested: 10:34:36
First Dose M/F: 03/17/05 / 03/18/05
Lab: BAT

F1_Rev.1_M3

NTP Study Number: C99031
Lock Date: 05/05/2008
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.6.0.0_007
PWG Approval Date: 04/14/2011

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
------------------	---------	-----------	-----------	------------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Accidentally Killed			1	
Moribund Sacrifice	8	16	23	13
Natural Death	8	7	5	14
Survivors				
Terminal Sacrifice	34	27	21	23
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(46)	(48)	(44)	(46)
Hyperplasia, Cystic Inflammation	2 (4%)			1 (2%)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid Epithelium, Hyperplasia	3 (6%) 1 (2%)		2 (4%)	1 (2%)
Intestine Large, Colon	(50)	(50)	(50)	(50)
Epithelium, Hyperplasia		1 (2%)		
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Ectopic Tissue	1 (2%)			1 (2%)
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid Inflammation Epithelium, Hyperplasia	3 (6%) 3 (6%)		1 (2%) 1 (2%)	1 (2%)
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid Inflammation Mineralization Epithelium, Hyperplasia	7 (14%) 3 (6%) 1 (2%) 1 (2%)	1 (2%)	6 (12%) 1 (2%)	2 (4%)
Liver	(50)	(50)	(50)	(50)
Angiectasis	2 (4%)			

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
Basophilic Focus	15 (30%)	14 (28%)	5 (10%)	4 (8%)
Clear Cell Focus	21 (42%)	22 (44%)	14 (28%)	12 (24%)
Eosinophilic Focus	34 (68%)	41 (82%)	36 (72%)	39 (78%)
Erythrophagocytosis		4 (8%)	11 (22%)	7 (14%)
Fatty Change, Focal	4 (8%)	3 (6%)		
Hematopoietic Cell Proliferation	4 (8%)	9 (18%)	12 (24%)	14 (28%)
Hepatodiaphragmatic Nodule	1 (2%)			
Hypertrophy	3 (6%)	19 (38%)	35 (70%)	23 (46%)
Infiltration Cellular, Lymphoid	1 (2%)			
Inflammation	28 (56%)	35 (70%)	42 (84%)	39 (78%)
Mixed Cell Focus	15 (30%)	13 (26%)	12 (24%)	9 (18%)
Necrosis	9 (18%)	15 (30%)	17 (34%)	19 (38%)
Tension Lipidosis	6 (12%)	1 (2%)		1 (2%)
Vacuolization Cytoplasmic	16 (32%)	13 (26%)	14 (28%)	14 (28%)
Bile Duct, Hyperplasia		2 (4%)	1 (2%)	2 (4%)
Hepatocyte, Hyperplasia			1 (2%)	
Vein, Thrombosis			1 (2%)	
Mesentery	(5)	(6)	(3)	(4)
Inflammation		2 (33%)	2 (67%)	2 (50%)
Fat, Necrosis	5 (100%)	4 (67%)		
Pancreas	(50)	(50)	(50)	(50)
Atrophy	1 (2%)		1 (2%)	
Cyst			1 (2%)	
Infiltration Cellular, Lymphoid				2 (4%)
Inflammation		1 (2%)		2 (4%)
Salivary Glands	(50)	(50)	(50)	(50)
Infiltration Cellular, Lymphoid	5 (10%)	4 (8%)	5 (10%)	1 (2%)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Cyst		1 (2%)		
Infiltration Cellular, Mast Cell			1 (2%)	
Inflammation	11 (22%)	24 (48%)	21 (42%)	45 (90%)
Mineralization		2 (4%)	1 (2%)	
Epithelium, Erosion		2 (4%)	1 (2%)	3 (6%)
Epithelium, Hyperkeratosis	11 (22%)	24 (48%)	24 (48%)	46 (92%)
Epithelium, Hyperplasia	14 (28%)	27 (54%)	27 (54%)	45 (90%)
Epithelium, Ulcer	7 (14%)	10 (20%)	12 (24%)	24 (48%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
Stomach, Glandular	(50)	(50)	(50)	(50)
Cyst	1 (2%)			1 (2%)
Inflammation	2 (4%)		1 (2%)	1 (2%)
Mineralization		2 (4%)	1 (2%)	
Epithelium, Hyperplasia	4 (8%)	5 (10%)	7 (14%)	4 (8%)
Tooth	(50)	(50)	(50)	(50)
Dysplasia	46 (92%)	46 (92%)	40 (80%)	33 (66%)

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(50)	(50)	(50)
Inflammation		1 (2%)		
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	38 (76%)	22 (44%)	27 (54%)	25 (50%)
Inflammation	1 (2%)	3 (6%)		
Mineralization	1 (2%)		2 (4%)	
Thrombosis	1 (2%)	1 (2%)		1 (2%)
Artery, Inflammation		1 (2%)		

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(50)	(50)
Hematopoietic Cell Proliferation	1 (2%)			
Hyperplasia	1 (2%)			
Hypertrophy	9 (18%)		3 (6%)	1 (2%)
Subcapsular, Hyperplasia	41 (82%)	39 (78%)	42 (84%)	43 (86%)
Adrenal Medulla	(50)	(50)	(50)	(49)
Hyperplasia	2 (4%)	1 (2%)		2 (4%)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	39 (78%)	38 (76%)	44 (88%)	35 (70%)
Parathyroid Gland	(36)	(46)	(46)	(44)
Pituitary Gland	(49)	(50)	(50)	(49)
Cyst				1 (2%)
Inflammation	1 (2%)			
Pars Distalis, Hyperplasia	2 (4%)		1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
Thyroid Gland	(49)	(49)	(50)	(50)
Cyst			1 (2%)	
Ultimobranchial Cyst	8 (16%)	3 (6%)	1 (2%)	
C-cell, Hyperplasia	2 (4%)	5 (10%)		
Follicle, Cyst	2 (4%)	1 (2%)		
Follicle, Hyperplasia	2 (4%)	1 (2%)	7 (14%)	25 (50%)
Follicular Cell, Degeneration		1 (2%)		
Follicular Cell, Hypertrophy	2 (4%)		2 (4%)	38 (76%)

GENERAL BODY SYSTEM

Peritoneum	(0)	(1)	(2)	(2)
Inflammation		1 (100%)	2 (100%)	2 (100%)

GENITAL SYSTEM

Epididymis	(50)	(50)	(50)	(50)
Hemorrhage	1 (2%)			
Infiltration Cellular, Lymphoid	3 (6%)	4 (8%)	3 (6%)	2 (4%)
Inflammation	1 (2%)	3 (6%)	2 (4%)	3 (6%)
Preputial Gland	(50)	(50)	(50)	(50)
Cyst		1 (2%)		
Ectasia	4 (8%)	3 (6%)	5 (10%)	8 (16%)
Fibrosis				1 (2%)
Infiltration Cellular, Lymphoid	1 (2%)			
Inflammation	30 (60%)	42 (84%)	49 (98%)	46 (92%)
Prostate	(50)	(50)	(49)	(50)
Hyperplasia	7 (14%)	3 (6%)	1 (2%)	1 (2%)
Infiltration Cellular, Lymphoid		3 (6%)	1 (2%)	
Inflammation	3 (6%)	5 (10%)	4 (8%)	4 (8%)
Seminal Vesicle	(50)	(50)	(50)	(50)
Dilatation	2 (4%)		1 (2%)	
Hyperplasia	1 (2%)		1 (2%)	
Inflammation	2 (4%)	2 (4%)		1 (2%)
Testes	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
Inflammation		1 (2%)		2 (4%)
Mineralization		3 (6%)		2 (4%)

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Hyperplasia	48 (96%)	49 (98%)	49 (98%)	50 (100%)
Lymph Node	(11)	(15)	(18)	(14)
Bronchial, Hyperplasia, Lymphoid	6 (55%)	2 (13%)	1 (6%)	4 (29%)
Bronchial, Infiltration Cellular, Histiocyte				1 (7%)
Inguinal, Hyperplasia, Lymphoid	6 (55%)	10 (67%)	16 (89%)	11 (79%)
Mediastinal, Hyperplasia, Lymphoid		1 (7%)		
Mediastinal, Infiltration Cellular, Histiocyte			1 (6%)	
Lymph Node, Mandibular	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid	17 (34%)	14 (28%)	16 (32%)	5 (10%)
Infiltration Cellular, Histiocyte			1 (2%)	1 (2%)
Lymph Node, Mesenteric	(50)	(49)	(49)	(50)
Hyperplasia, Lymphoid	6 (12%)	5 (10%)	10 (20%)	1 (2%)
Inflammation		1 (2%)	1 (2%)	
Spleen	(50)	(50)	(50)	(50)
Angiectasis		1 (2%)		
Hematopoietic Cell Proliferation	49 (98%)	47 (94%)	50 (100%)	50 (100%)
Hyperplasia				1 (2%)
Hyperplasia, Lymphoid	9 (18%)	12 (24%)	6 (12%)	8 (16%)
Lymphoid Follicle, Atrophy		1 (2%)		
Thymus	(50)	(47)	(50)	(45)
Atrophy	1 (2%)			
Hyperplasia, Lymphoid	10 (20%)	10 (21%)	19 (38%)	10 (22%)
Necrosis		1 (2%)		

INTEGUMENTARY SYSTEM

Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
Dermis, Fibrosis	2 (4%)		1 (2%)	
Dermis, Inflammation	2 (4%)	2 (4%)	1 (2%)	
Dermis, Subcutaneous Tissue, Inflammation		1 (2%)		
Epidermis, Hyperkeratosis	1 (2%)	1 (2%)		
Epidermis, Hyperplasia	2 (4%)	1 (2%)	1 (2%)	
Epidermis, Ulcer	2 (4%)	2 (4%)	1 (2%)	
Subcutaneous Tissue, Inflammation		2 (4%)		
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Hyperplasia			1 (2%)	
Vertebra, Fracture			1 (2%)	
Skeletal Muscle	(1)	(1)	(1)	(1)
Cyst				1 (100%)
Hemorrhage			1 (100%)	
Inflammation	1 (100%)			1 (100%)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Hemorrhage		1 (2%)		
Infiltration Cellular, Lymphoid	2 (4%)			1 (2%)
Peripheral Nerve	(0)	(0)	(1)	(0)
Spinal, Hemorrhage			1 (100%)	
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Infiltration Cellular, Histiocyte	1 (2%)			
Inflammation	5 (10%)	1 (2%)	6 (12%)	3 (6%)
Metaplasia, Osseous				1 (2%)
Mineralization	2 (4%)	1 (2%)		1 (2%)
Pigmentation			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
Alveolar Epithelium, Hyperplasia	4 (8%)	3 (6%)	1 (2%)	1 (2%)
Alveolus, Infiltration Cellular, Histiocyte	10 (20%)	7 (14%)	11 (22%)	5 (10%)
Nose	(50)	(50)	(50)	(50)
Inflammation	7 (14%)	16 (32%)	5 (10%)	9 (18%)
Glands, Metaplasia	1 (2%)			
Glands, Metaplasia, Respiratory	3 (6%)	3 (6%)	2 (4%)	1 (2%)
Olfactory Epithelium, Accumulation, Hyaline Droplet	18 (36%)	16 (32%)	15 (30%)	28 (56%)
Olfactory Epithelium, Atrophy		3 (6%)		
Olfactory Epithelium, Degeneration	1 (2%)			
Olfactory Epithelium, Hyperplasia	2 (4%)			1 (2%)
Olfactory Epithelium, Metaplasia	1 (2%)			
Olfactory Epithelium, Metaplasia, Respiratory	3 (6%)	3 (6%)		
Olfactory Epithelium, Pigmentation		1 (2%)	3 (6%)	13 (26%)
Respiratory Epithelium, Hyperplasia	40 (80%)	38 (76%)	37 (74%)	33 (66%)
Trachea	(50)	(50)	(50)	(50)

SPECIAL SENSES SYSTEM

Ear	(1)	(0)	(0)	(1)
Eye	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Cataract			1 (2%)	
Inflammation	1 (2%)			
Cornea, Hyperplasia, Squamous	1 (2%)	1 (2%)	3 (6%)	
Cornea, Inflammation	1 (2%)	1 (2%)	3 (6%)	1 (2%)
Harderian Gland	(50)	(50)	(50)	(50)
Atrophy		1 (2%)		
Cyst				1 (2%)
Fibrosis		1 (2%)		
Hyperplasia	3 (6%)	5 (10%)	3 (6%)	2 (4%)
Infiltration Cellular, Lymphoid		1 (2%)	1 (2%)	
Mineralization		1 (2%)		
Pigmentation	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
<hr/>				
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Accumulation, Hyaline Droplet		1 (2%)		
Cyst	6 (12%)	6 (12%)	8 (16%)	5 (10%)
Infarct	2 (4%)	2 (4%)		
Infiltration Cellular, Lymphoid	2 (4%)	1 (2%)	1 (2%)	
Inflammation	2 (4%)	4 (8%)	1 (2%)	1 (2%)
Metaplasia, Osseous	3 (6%)	4 (8%)	4 (8%)	
Mineralization	40 (80%)	40 (80%)	38 (76%)	21 (42%)
Nephropathy	49 (98%)	45 (90%)	44 (88%)	39 (78%)
Pigmentation	3 (6%)	15 (30%)	26 (52%)	19 (38%)
Pelvis, Dilatation			1 (2%)	
Renal Tubule, Hyperplasia	1 (2%)	1 (2%)		
Renal Tubule, Necrosis		1 (2%)		
Urethra	(0)	(1)	(0)	(0)
Bulbourethral Gland, Inflammation		1 (100%)		
Urinary Bladder	(50)	(50)	(50)	(50)
Hemorrhage		1 (2%)		
Inflammation	2 (4%)	2 (4%)		1 (2%)

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
Disposition Summary				
Animals Initially In Study	50	50	50	50
Early Deaths				
Accidentally Killed		2		
Dosing Accident	5		1	
Moribund Sacrifice	8	8	3	3
Natural Death	6	4	3	11
Survivors				
Terminal Sacrifice	31	36	43	36
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Inflammation	5 (10%)		1 (2%)	
Perforation	4 (8%)			
Gallbladder	(50)	(50)	(48)	(48)
Cyst		3 (6%)		
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid				1 (2%)
Inflammation			1 (2%)	
Necrosis		1 (2%)		
Intestine Large, Colon	(50)	(50)	(50)	(50)
Inflammation				1 (2%)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Epithelium, Hyperplasia	1 (2%)			
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Inflammation	1 (2%)			
Epithelium, Hyperplasia	1 (2%)			
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid			1 (2%)	
Liver	(50)	(50)	(50)	(50)
Basophilic Focus	7 (14%)	8 (16%)	9 (18%)	9 (18%)
Clear Cell Focus	1 (2%)	3 (6%)	2 (4%)	6 (12%)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
Eosinophilic Focus	26 (52%)	39 (78%)	43 (86%)	45 (90%)
Erythrophagocytosis		3 (6%)	7 (14%)	16 (32%)
Fatty Change, Focal	1 (2%)	1 (2%)	2 (4%)	3 (6%)
Hematopoietic Cell Proliferation	14 (28%)	12 (24%)	9 (18%)	4 (8%)
Hypertrophy		18 (36%)	37 (74%)	37 (74%)
Inflammation	38 (76%)	45 (90%)	46 (92%)	41 (82%)
Mineralization				1 (2%)
Mixed Cell Focus	7 (14%)	27 (54%)	31 (62%)	31 (62%)
Necrosis	4 (8%)	2 (4%)	6 (12%)	11 (22%)
Tension Lipidosis	5 (10%)	11 (22%)	10 (20%)	3 (6%)
Vacuolization Cytoplasmic	18 (36%)	38 (76%)	44 (88%)	35 (70%)
Bile Duct, Cyst		2 (4%)	1 (2%)	
Mesentery	(3)	(5)	(3)	(4)
Inflammation			1 (33%)	1 (25%)
Fat, Necrosis	2 (67%)	5 (100%)	3 (100%)	2 (50%)
Oral Mucosa	(1)	(0)	(0)	(0)
Pancreas	(50)	(49)	(50)	(50)
Atrophy	1 (2%)	4 (8%)	4 (8%)	1 (2%)
Cyst	1 (2%)			
Infiltration Cellular, Lymphoid		3 (6%)	1 (2%)	
Inflammation			1 (2%)	2 (4%)
Acinus, Hyperplasia			1 (2%)	
Acinus, Hypertrophy	1 (2%)			
Duct, Cyst		1 (2%)	3 (6%)	1 (2%)
Salivary Glands	(50)	(50)	(49)	(50)
Infiltration Cellular, Lymphoid	3 (6%)	2 (4%)	2 (4%)	1 (2%)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Inflammation	4 (8%)	6 (12%)	5 (10%)	19 (38%)
Mineralization		1 (2%)		
Epithelium, Erosion		1 (2%)		
Epithelium, Hyperkeratosis	3 (6%)	11 (22%)	5 (10%)	20 (40%)
Epithelium, Hyperplasia	8 (16%)	18 (36%)	11 (22%)	20 (40%)
Epithelium, Ulcer	1 (2%)	1 (2%)	1 (2%)	11 (22%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Cyst		1 (2%)	2 (4%)	1 (2%)
Inflammation		2 (4%)	1 (2%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
Mineralization	1 (2%)			
Epithelium, Hyperplasia	2 (4%)	2 (4%)	1 (2%)	5 (10%)
Tooth	(50)	(50)	(50)	(50)
Dysplasia		4 (8%)	3 (6%)	

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(49)	(50)	(50)
Mineralization	1 (2%)	1 (2%)		
Aorta, Inflammation	1 (2%)			
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	7 (14%)	5 (10%)	5 (10%)	7 (14%)
Inflammation	2 (4%)	1 (2%)		
Mineralization	2 (4%)	2 (4%)	3 (6%)	
Necrosis		1 (2%)		
Epicardium, Inflammation	2 (4%)		1 (2%)	

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)			
Hematopoietic Cell Proliferation	5 (10%)	1 (2%)	3 (6%)	3 (6%)
Hypertrophy	1 (2%)			
Infiltration Cellular, Lymphoid			1 (2%)	1 (2%)
Subcapsular, Hyperplasia	46 (92%)	50 (100%)	49 (98%)	50 (100%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia		1 (2%)		
Hypertrophy				1 (2%)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Hyperplasia	7 (14%)	11 (22%)	11 (22%)	9 (18%)
Parathyroid Gland	(47)	(46)	(45)	(45)
Hyperplasia	1 (2%)	1 (2%)	1 (2%)	
Infiltration Cellular, Lymphoid			2 (4%)	
Pituitary Gland	(50)	(50)	(49)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
Angiectasis		1 (2%)		
Pars Distalis, Hyperplasia	14 (28%)	20 (40%)	22 (45%)	10 (20%)
Thyroid Gland	(49)	(48)	(49)	(48)
Ultimobranchial Cyst	14 (29%)	7 (15%)	9 (18%)	3 (6%)
C-cell, Hyperplasia	3 (6%)	6 (13%)	5 (10%)	1 (2%)
Follicle, Cyst	3 (6%)	1 (2%)	2 (4%)	1 (2%)
Follicle, Hyperplasia			4 (8%)	
Follicular Cell, Degeneration			1 (2%)	
Follicular Cell, Hypertrophy	1 (2%)	5 (10%)	9 (18%)	39 (81%)

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

Clitoral Gland	(50)	(50)	(50)	(49)
Inflammation	4 (8%)	2 (4%)	1 (2%)	
Ovary	(50)	(50)	(49)	(50)
Angiectasis	2 (4%)			2 (4%)
Cyst	8 (16%)	10 (20%)	17 (35%)	11 (22%)
Hemorrhage, Chronic		1 (2%)		
Mineralization	1 (2%)		1 (2%)	
Thrombosis	1 (2%)		1 (2%)	
Germinal Epithelium, Hyperplasia			1 (2%)	
Uterus	(50)	(50)	(50)	(50)
Angiectasis			1 (2%)	1 (2%)
Dysplasia				1 (2%)
Fibrosis	1 (2%)			
Hemorrhage			1 (2%)	
Inflammation	7 (14%)	10 (20%)	3 (6%)	2 (4%)
Malformation		1 (2%)		
Artery, Dysplasia			1 (2%)	
Endometrium, Decidual Reaction	1 (2%)			
Endometrium, Hyperplasia	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
Endometrium, Hyperplasia, Cystic	35 (70%)	37 (74%)	35 (70%)	30 (60%)

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)
Hyperplasia	38 (76%)	43 (86%)	42 (84%)	36 (72%)
Necrosis		1 (2%)		
Lymph Node	(16)	(11)	(11)	(6)
Bronchial, Hyperplasia, Lymphoid	3 (19%)	3 (27%)	2 (18%)	1 (17%)
Inguinal, Hyperplasia, Lymphoid	7 (44%)	2 (18%)	2 (18%)	3 (50%)
Mediastinal, Hyperplasia, Lymphoid		2 (18%)		1 (17%)
Pancreatic, Angiectasis	1 (6%)			
Pancreatic, Hyperplasia, Lymphoid	1 (6%)		1 (9%)	
Renal, Angiectasis	1 (6%)			
Renal, Ectasia			1 (9%)	
Renal, Hemorrhage, Chronic			1 (9%)	
Renal, Sinus, Ectasia			1 (9%)	
Lymph Node, Bronchial	(0)	(0)	(0)	(1)
Lymph Node, Mandibular	(49)	(50)	(49)	(50)
Angiectasis			1 (2%)	
Hyperplasia, Lymphoid	6 (12%)	15 (30%)	10 (20%)	7 (14%)
Inflammation	1 (2%)			
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid	6 (12%)	5 (10%)	2 (4%)	
Inflammation			1 (2%)	
Spleen	(50)	(50)	(50)	(50)
Hematopoietic Cell Proliferation	48 (96%)	48 (96%)	50 (100%)	50 (100%)
Hyperplasia, Lymphoid	20 (40%)	33 (66%)	25 (50%)	29 (58%)
Mineralization		1 (2%)		
Necrosis			1 (2%)	
Pigmentation	4 (8%)			
Lymphoid Follicle, Atrophy			1 (2%)	1 (2%)
Thymus	(50)	(49)	(49)	(50)
Angiectasis				1 (2%)
Hyperplasia, Lymphoid	18 (36%)	16 (33%)	23 (47%)	13 (26%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
Inflammation			1 (2%)	
Necrosis	3 (6%)			
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Hyperplasia	3 (6%)			
Inflammation			1 (2%)	
Skin	(50)	(50)	(50)	(50)
Dermis, Inflammation	1 (2%)		1 (2%)	
Epidermis, Hyperplasia	1 (2%)			
Epidermis, Ulcer	1 (2%)			
Sebaceous Gland, Hyperplasia	1 (2%)			
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Fracture		2 (4%)		
Osteopetrosis			1 (2%)	
Osteoporosis	7 (14%)	16 (32%)	17 (34%)	6 (12%)
Synovial Tissue, Inflammation		1 (2%)		
Skeletal Muscle	(1)	(1)	(0)	(0)
NERVOUS SYSTEM				
Brain	(50)	(50)	(49)	(50)
Gliosis	1 (2%)	1 (2%)		
Hemorrhage		1 (2%)		
Peripheral Nerve	(1)	(1)	(1)	(0)
Sciatic, Demyelination	1 (100%)			
Spinal, Demyelination	1 (100%)			
Spinal Cord	(0)	(1)	(1)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Cyst			1 (2%)	
Hemorrhage		2 (4%)		
Infiltration Cellular, Histiocyte		3 (6%)	2 (4%)	3 (6%)
Inflammation		5 (10%)	3 (6%)	7 (14%)
Metaplasia, Osseous	1 (2%)			1 (2%)
Mineralization		1 (2%)		
Thrombosis	1 (2%)			
Vacuolization Cytoplasmic				1 (2%)
Alveolar Epithelium, Hyperplasia	1 (2%)	1 (2%)		
Alveolar Epithelium, Inflammation	1 (2%)			
Arteriole, Hyperplasia				3 (6%)
Bronchiole, Hyperplasia		1 (2%)		
Pleura, Inflammation	5 (10%)		1 (2%)	
Smooth Muscle, Proliferation				1 (2%)
Nose	(50)	(50)	(50)	(50)
Inflammation	4 (8%)	5 (10%)	4 (8%)	6 (12%)
Glands, Metaplasia	3 (6%)	4 (8%)	5 (10%)	2 (4%)
Olfactory Epithelium, Accumulation, Hyaline Droplet	5 (10%)	3 (6%)	12 (24%)	17 (34%)
Olfactory Epithelium, Atrophy			1 (2%)	1 (2%)
Olfactory Epithelium, Degeneration	3 (6%)			
Olfactory Epithelium, Hyperplasia	1 (2%)			
Olfactory Epithelium, Metaplasia	1 (2%)			
Olfactory Epithelium, Pigmentation		1 (2%)	6 (12%)	13 (26%)
Respiratory Epithelium, Hyperplasia	15 (30%)	15 (30%)	18 (36%)	15 (30%)
Trachea	(50)	(50)	(50)	(50)

SPECIAL SENSES SYSTEM

Ear	(1)	(0)	(0)	(0)
Eye	(50)	(50)	(49)	(50)
Cataract		1 (2%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99031 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Ginkgo biloba extract

CAS Number: 90045-36-6

Date Report Requested: 02/27/2012

Time Report Requested: 10:34:36

First Dose M/F: 03/17/05 / 03/18/05

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	200 mg/kg	600 mg/kg	2000 mg/kg
Phthisis Bulbi		1 (2%)		
Anterior Chamber, Inflammation	1 (2%)			1 (2%)
Cornea, Inflammation	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Harderian Gland	(50)	(50)	(49)	(50)
Fibrosis			1 (2%)	
Hyperplasia	2 (4%)	1 (2%)	2 (4%)	4 (8%)
Infiltration Cellular, Lymphoid	1 (2%)			1 (2%)
Inflammation			1 (2%)	1 (2%)
<hr/>				
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Accumulation, Hyaline Droplet			1 (2%)	
Cyst	1 (2%)		3 (6%)	3 (6%)
Dilatation		1 (2%)		
Glomerulopathy				1 (2%)
Infarct	1 (2%)		1 (2%)	
Infiltration Cellular, Lymphoid				1 (2%)
Inflammation	1 (2%)		2 (4%)	
Metaplasia, Osseous	1 (2%)	1 (2%)	1 (2%)	
Mineralization	11 (22%)	8 (16%)	3 (6%)	10 (20%)
Nephropathy	24 (48%)	17 (34%)	15 (30%)	14 (28%)
Pigmentation			2 (4%)	1 (2%)
Glomerulus, Amyloid Deposition	1 (2%)			
Pelvis, Dilatation				1 (2%)
Urinary Bladder	(50)	(50)	(50)	(50)
Infiltration Cellular, Lymphoid	6 (12%)	2 (4%)	2 (4%)	8 (16%)
Inflammation			1 (2%)	

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion